Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 8/20 | 0.52 |
| ▸ | MAOA | P21397 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20483281 | 0.84 | NR1H4 (0.57) | PTGESPTGS2MAOBMAOACASP3 | |
| SCHEMBL7952747 | 0.80 | MAOA (0.77) | PTGESPTGS2MAOBMAOACASP3 | |
| SCHEMBL16319027 | 0.79 | MEN1 (0.53) | MAOBNPC1RAB9AL3MBTL1PKM | |
| SCHEMBL18538451 | 0.79 | MEN1 (0.56) | MAOBL3MBTL1MEN1KMT2AHSP90AA1 | |
| SCHEMBL16319026 | 0.79 | MEN1 (0.53) | MAOBNPC1RAB9AL3MBTL1PKM | |
| SCHEMBL30106288 | 0.79 | MEN1 (0.56) | MAOBL3MBTL1MEN1KMT2AHSP90AA1 | |
| SCHEMBL10638962 | 0.79 | MEN1 (0.56) | MAOBL3MBTL1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1549368 | 0.79 | MEN1 (0.56) | L3MBTL1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL1549366 | 0.79 | MEN1 (0.56) | L3MBTL1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL433576 | 0.78 | HDAC8 (0.68) | L3MBTL1MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | PTGES 1638/4885PTGS2 1279/4885MAOB 4207/4885 |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | HGF, SMAD3, HRAS | PTGES 1638/4885PTGS2 1279/4885MAOB 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.